NO335739B1 - Farmasøytisk preparat av den kalsiumreseptoraktive forbindelsen cinacalet-HCl og dets anvendelse til fremstilling av et medikament - Google Patents
Farmasøytisk preparat av den kalsiumreseptoraktive forbindelsen cinacalet-HCl og dets anvendelse til fremstilling av et medikament Download PDFInfo
- Publication number
- NO335739B1 NO335739B1 NO20061640A NO20061640A NO335739B1 NO 335739 B1 NO335739 B1 NO 335739B1 NO 20061640 A NO20061640 A NO 20061640A NO 20061640 A NO20061640 A NO 20061640A NO 335739 B1 NO335739 B1 NO 335739B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- weight
- preparation according
- hcl
- relative
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 129
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
- 239000003814 drug Substances 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 title abstract description 41
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 title abstract description 31
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 title abstract description 31
- 229940079593 drug Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 61
- 239000008187 granular material Substances 0.000 claims description 31
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 claims description 28
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 21
- 229940069328 povidone Drugs 0.000 claims description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 17
- 239000008107 starch Substances 0.000 claims description 17
- 235000019698 starch Nutrition 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 230000000148 hypercalcaemia Effects 0.000 claims description 6
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 4
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 4
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 4
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000005029 sieve analysis Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 229940032147 starch Drugs 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000009826 distribution Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 238000007922 dissolution test Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012738 dissolution medium Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 2
- 229960003315 cinacalcet Drugs 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VIAMIUDTTIDZCA-TYYBGVCCSA-N (e)-but-2-enedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)\C=C\C(O)=O VIAMIUDTTIDZCA-TYYBGVCCSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940090761 vitamin d and analogues Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50221903P | 2003-09-12 | 2003-09-12 | |
| PCT/US2004/026732 WO2005034928A1 (en) | 2003-09-12 | 2004-09-10 | Rapid dissolution formulation of a calcium receptor-active compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20061640L NO20061640L (no) | 2006-06-12 |
| NO335739B1 true NO335739B1 (no) | 2015-02-02 |
Family
ID=34434844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061640A NO335739B1 (no) | 2003-09-12 | 2006-04-11 | Farmasøytisk preparat av den kalsiumreseptoraktive forbindelsen cinacalet-HCl og dets anvendelse til fremstilling av et medikament |
Country Status (30)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004279318C1 (en) | 2003-09-12 | 2020-06-25 | Amgen Inc. | Rapid dissolution formulation of a calcium receptor-active compound |
| ME02799B (me) | 2004-06-24 | 2018-01-20 | Vertex Pharma | Modulatori ATP-vezujućih kasetnih transportera |
| ATE443038T1 (de) * | 2005-05-16 | 2009-10-15 | Teva Pharma | Verfahren zur herstellung von cinacalcet hydrochlorid |
| WO2006127941A2 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Amorphous cinacalcet hydrochloride and preparation thereof |
| CA2606099A1 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Processes for preparing cinacalcet hydrochloride crystal form i |
| WO2006126681A1 (ja) | 2005-05-26 | 2006-11-30 | Dainippon Sumitomo Pharma Co., Ltd. | 医薬品組成物 |
| JP5244597B2 (ja) * | 2005-09-02 | 2013-07-24 | アムジエン・インコーポレーテツド | カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法 |
| KR20080055990A (ko) * | 2005-11-22 | 2008-06-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법 |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| ES2904546T3 (es) | 2006-02-03 | 2022-04-05 | Opko Renal Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
| EP2001832A1 (en) * | 2006-03-23 | 2008-12-17 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| EP1928817A1 (en) * | 2006-04-27 | 2008-06-11 | Teva Pharmaceutical Industries Ltd | Process for the preparation of cinacalcet base |
| US7449603B2 (en) * | 2006-04-27 | 2008-11-11 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of cinacalcet base |
| SI2037936T1 (sl) | 2006-06-21 | 2014-11-28 | Opko Renal, Llc | Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma |
| US20090258949A1 (en) * | 2006-06-27 | 2009-10-15 | Johannes Ludescher | Amorphous form of cinacalcet |
| BRPI0715635A2 (pt) * | 2006-09-01 | 2013-07-02 | Teva Pharma | compàsitos sàlidos de um composto de cÁlcio receptor-ativo |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| US20080146845A1 (en) * | 2006-11-20 | 2008-06-19 | Boaz Gome | Process for preparing Cinacalcet |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| WO2008122010A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals, Inc. | Pharmaceutical calcimimetics |
| CA2683628C (en) | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| WO2009002427A2 (en) | 2007-06-21 | 2008-12-31 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
| WO2009025792A2 (en) * | 2007-08-16 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| EP2300415A2 (en) * | 2008-05-05 | 2011-03-30 | Medichem, S.A. | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| WO2010034497A2 (de) | 2008-09-25 | 2010-04-01 | Ratiopharm Gmbh | Kompaktiertes cinacalcet |
| WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| JP2012528086A (ja) | 2009-05-27 | 2012-11-12 | レオ ファーマ アクティーゼルスカブ | 新規のカルシウム感知受容体調節化合物およびその医薬用途 |
| CA2762130A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
| CN105796530A (zh) | 2010-03-29 | 2016-07-27 | 赛特克罗公司 | 用于降低甲状旁腺水平的方法和组合物 |
| CN103347517B (zh) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
| HUE049344T2 (hu) * | 2010-11-23 | 2020-09-28 | Amgen Inc | Gyermekgyógyászati készítmény |
| JP2014508104A (ja) | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| CN103228629A (zh) | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 作为CaSR活性化合物的被取代的环戊基-氮杂苯类 |
| JP2014507375A (ja) | 2010-11-26 | 2014-03-27 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| JP2014508103A (ja) | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| BR112014015003A2 (pt) * | 2011-12-19 | 2019-09-24 | Amgen Inc | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral |
| EP2804588B1 (en) | 2012-01-17 | 2017-09-06 | Zentiva Saglik Urunleri San. Ve Tic. A.S. | Method for producing cinacalcet compositions for direct tableting |
| HK1203840A1 (en) | 2012-02-27 | 2015-11-06 | 沃泰克斯药物股份有限公司 | Pharmaceutical composition and administration thereof |
| CN102885792A (zh) * | 2012-10-12 | 2013-01-23 | 华润赛科药业有限责任公司 | 盐酸西那卡塞的口服固体速释制剂 |
| ES2547577T3 (es) * | 2012-11-09 | 2015-10-07 | K.H.S. Pharma Holding Gmbh | Formulaciones de liberación inmediata de cinacalcet |
| US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
| US9895325B2 (en) | 2012-12-21 | 2018-02-20 | Synthon B.V. | Tablet composition comprising cinacalcet hydrochloride |
| EA201591423A1 (ru) | 2013-02-01 | 2016-01-29 | Санта Мария Биотерапевтикс, Инк. | Введение антитела к активину-а пациентам |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| WO2014207691A1 (en) | 2013-06-26 | 2014-12-31 | Jubilant Life Sciences Limited | Disintegrant free composition of cinacalcet |
| WO2015136329A1 (en) * | 2014-03-14 | 2015-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition of cinacalcet |
| WO2015150944A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
| CN104721164B (zh) * | 2015-03-25 | 2017-07-07 | 河北仁合益康药业有限公司 | 一种盐酸西那卡塞薄膜衣片组合物 |
| UA129792C2 (uk) | 2016-03-28 | 2025-08-06 | Ейрджен Фарма Лтд. | Способи лікування вітаміном d |
| CA3019508A1 (en) | 2016-03-31 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
| US11331283B2 (en) * | 2017-08-16 | 2022-05-17 | Unichem Laboratories Ltd | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders |
| EP3773533A1 (en) | 2018-03-30 | 2021-02-17 | FTF Pharma Private Limited | Liquid dosage forms of cinacalcet or salt thereof |
| US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
| RU2750761C2 (ru) * | 2019-09-17 | 2021-07-02 | Общество с ограниченной ответственностью "АМЕДАРТ" | Ядро таблетки, содержащей цинакальцета гидрохлорид |
| EP4110304A4 (en) * | 2020-02-29 | 2024-06-05 | Zevra Therapeutics, Inc. | COMPOSITIONS COMPRISING METHYLPHENIDATE PRODRUGS, METHODS OF PREPARATION THEREOF AND METHODS OF USE |
| CN112546010A (zh) * | 2020-12-02 | 2021-03-26 | 普莱赛思(天津)生命科技有限公司 | 一种肾病药物组合物及其制备方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| IL88150A0 (en) | 1987-11-02 | 1989-06-30 | Merck & Co Inc | Pharmaceutical tablet compositions containing phthalizine acetic acid compounds |
| EP0357815A1 (de) | 1988-09-06 | 1990-03-14 | Siemens Aktiengesellschaft | Schaltbare Konstantstromquelle mit I2L-Gattern |
| KR900701255A (ko) | 1988-11-30 | 1990-12-01 | 스테이너 브이.캔스타드 | 서방성 딜티아젬 제제 |
| NZ231897A (en) | 1988-12-30 | 1992-09-25 | Monsanto Co | Dry water-soluble granular composition comprising glyphosate and a liquid surfactant |
| US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US4931286A (en) | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
| DD299322A5 (de) * | 1989-09-21 | 1992-04-09 | Maschinenfabrik Rieter Ag,Ch | Verfahren und vorrichtung zur feinreinigung von textilfasern |
| US5011068A (en) * | 1989-12-05 | 1991-04-30 | Progressive Tool & Industries Co. | Automotive body framing system |
| WO1995011221A1 (en) | 1991-08-23 | 1995-04-27 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| ATE312347T1 (de) | 1991-08-23 | 2005-12-15 | Nps Pharma Inc | Screening-verfahren für kalzium-rezeptor aktive verbindungen |
| US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| DE69333527T2 (de) | 1993-02-23 | 2005-06-16 | Brigham & Women's Hospital, Inc., Boston | Calciumrezeptoraktive moleküle |
| US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| UA41909C2 (uk) * | 1994-07-22 | 2001-10-15 | Елі Ліллі Енд Компані | Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат |
| EP1275635A1 (en) * | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| GB9424766D0 (en) | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| DE19530575A1 (de) | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| DE69739388D1 (de) | 1996-05-01 | 2009-06-10 | Nps Pharma Inc | Inorganische am Ionen-Rezeptor aktive Verbindungen |
| US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
| US6362231B1 (en) | 1996-07-08 | 2002-03-26 | Nps Pharmaceuticals, Inc. | Calcium receptor active compounds |
| DE19637082A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| WO1999009458A1 (de) | 1997-08-13 | 1999-02-25 | OCé PRINTING SYSTEMS GMBH | Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern |
| CA2322315C (en) | 1998-03-06 | 2008-09-16 | Eurand International S.P.A. | Fast disintegrating tablets |
| US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
| JP2002527414A (ja) | 1998-10-14 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | １，２−ジ置換シクロプロパン |
| AU775094B2 (en) | 1998-11-23 | 2004-07-15 | Monsanto Technology Llc | Highly concentrated aqueous glyphosate compositions |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
| EP1239856A1 (en) | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| WO2001078725A2 (en) | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| WO2002024230A1 (en) | 2000-09-22 | 2002-03-28 | Takeda Chemical Industries, Ltd. | Solid preparations |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| IN191028B (cg-RX-API-DMAC7.html) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| ES2284871T3 (es) | 2001-06-22 | 2007-11-16 | Pfizer Products Inc. | Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad. |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| WO2003086343A2 (en) | 2002-04-05 | 2003-10-23 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
| US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| WO2004030669A1 (en) | 2002-09-30 | 2004-04-15 | Schering Corporation | Use of tricyclic amides for the treatment of disorders of calcium homeostasis |
| GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
| AU2004279318C1 (en) | 2003-09-12 | 2020-06-25 | Amgen Inc. | Rapid dissolution formulation of a calcium receptor-active compound |
| PT1713489E (pt) | 2004-08-23 | 2011-03-03 | Teva Pharma | Forma cristalina de ibandronato de sódio e processos para a sua preparação |
| NL1028867C2 (nl) | 2005-04-26 | 2006-10-27 | Xycarb Ceramics B V | Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting. |
| US8922209B2 (en) | 2008-03-11 | 2014-12-30 | The University Of Western Ontario | System and method for magnetic resonance imaging |
-
2004
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en not_active Expired
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en not_active Ceased
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/en not_active Expired - Lifetime
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es not_active Expired - Lifetime
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/en not_active Expired - Lifetime
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 CA CA2536487A patent/CA2536487C/en not_active Expired - Lifetime
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es not_active Expired - Lifetime
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en not_active IP Right Cessation
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/en not_active Revoked
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh not_active Expired - Lifetime
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko not_active Expired - Lifetime
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es not_active Expired - Lifetime
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/en not_active Revoked
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es not_active Expired - Lifetime
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 HR HRP20130114TT patent/HRP20130114T4/hr unknown
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es not_active Expired - Lifetime
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/en not_active Revoked
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/en not_active Revoked
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh not_active IP Right Cessation
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja not_active Expired - Lifetime
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es not_active Expired - Lifetime
- 2004-09-10 EP EP10014567A patent/EP2316442A1/en not_active Withdrawn
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/en not_active Revoked
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/en active
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
-
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
-
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
-
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
-
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
-
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
-
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO335739B1 (no) | Farmasøytisk preparat av den kalsiumreseptoraktive forbindelsen cinacalet-HCl og dets anvendelse til fremstilling av et medikament | |
| CN110946834A (zh) | 枸橼酸托法替布片及其制备工艺 | |
| CN108042502B (zh) | 一种盐酸胍法辛缓释片及其制备方法 | |
| NZ534587A (en) | Pharmaceutical composition containing 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid to treat a cyclooxygenase-2 dependent disorder | |
| HK40072206A (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |